White, Gary W.; Starr, Robin M.
Therapeutic Options for Canine Osteoarthritis
 

Abstract: The role of Disease-Modifying Osteoarthritis Drugs.  A wide variety of clinical cases of canine OA typical of the caseload seen in a small animal practice was studied.  Evidence was established that the Adequan Canine® (polysulfated glycosaminoglycan or PSGAG) treated group versus placebo showed a trend of greater percent improvement in the scores for each parameter:  Lameness at a walk, lameness at a trot, range of motion, pain, disability, and total orthopedic score.
Collier, M.A.; DeBault, Lawrence; Thompson, Harold; White, Gary W.; Jones, Wynn E.; Walls, Robert; Hamm, Jack;
The Distribution of Radiolabeled PSGAG in Canine Synovial Fluid and Articular Cartilage after Intramuscular Injection of3 HPSGAG.

 

This study supports therapeutic use of 2mg/lb of bodyweight by providing evidence of effective concentrations of PSGAG adequate for the drug's disease modifying mechanisms in canine synovial fluid within 2 hours of injections and maintaining these levels in the articular cartilage of inflamed joints for at least 72 hours.